IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
University of California, Davis
University of California, Davis
Tizona Therapeutics, Inc
City of Hope Medical Center
Jonsson Comprehensive Cancer Center
Rondo Therapeutics
Incyte Corporation
Toray Industries, Inc
Trishula Therapeutics, Inc.
Trishula Therapeutics, Inc.
Sotio Biotech Inc.
Carisma Therapeutics Inc
Southern Illinois University
Eli Lilly and Company
Northwestern University
ADC Therapeutics S.A.
Corvus Pharmaceuticals, Inc.
Rutgers, The State University of New Jersey
Viralytics
Evelo Biosciences, Inc.
University of California, Davis
Seagen Inc.
Dana-Farber Cancer Institute